[an error occurred while processing this directive] | [an error occurred while processing this directive]
Treatment modalities and clinical prognosis of 46 patients with nasopharyngeal adenoid cystic carcinoma
Sun Meng, Wang Kai, Qu Yuan, Zhang Shiping, Yi Junlin, Li Suyan, Xiao Jianping, Gao Li, Xu Guozhen, Huang Xiaodong, Luo Jingwei
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences ( CAMS ) and Peking Union Medical College (PUMC),Beijing 100021,China
AbstractObjective To analyze the clinical treatment modalities and clinical prognosis of patients diagnosed with primary nasopharyngeal adenoid cystic carcinoma (NACC). Methods The medical records of 46 patients with NACC between March 1971 and November 2015 were retrospectively analyzed. Among them, 22 patients were male and 24 female. The median age of all patients was 47 years (range:23-74 years). Among them,34 patients received radiotherapy alone including 25 patients treated with conventional radiotherapy and 9 receiving intensity-modulated radiation therapy (IMRT). Five patients underwent salvage surgery for the residual tumors after radiotherapy. Twelve patients were treated with a comprehensive treatment modality (surgery combined with radiotherapy). Results The median follow-up time was 66.0 months (range:11.0-270.6 months). The 5-and 10-year overall survival, locoregional failure-free survival, and distant metastasis failure-free survival rates were 70% and 40%,64% and 47%,70% and 62%,respectively. In the radiotherapy alone group,12(35%) cases obtained complete response,13 had partial response and 9 remained stable after radiotherapy. The 5-year overall survival and locoregional failure-free survival rates in the radiotherapy alone and combined therapy groups were 69% and 74%,63% and 66%, respectively (all P>0.05). Conclusion The course of NACC is relatively slow. Radiotherapy is recommended for patients with high sensitivity towards radiotherapy. Salvage surgery is feasible for those who are insensitive to radiotherapy or with residual tumor after radiotherapy.
Sun Meng,Wang Kai,Qu Yuan et al. Treatment modalities and clinical prognosis of 46 patients with nasopharyngeal adenoid cystic carcinoma[J]. Chinese Journal of Radiation Oncology, 2019, 28(7): 486-489.
Sun Meng,Wang Kai,Qu Yuan et al. Treatment modalities and clinical prognosis of 46 patients with nasopharyngeal adenoid cystic carcinoma[J]. Chinese Journal of Radiation Oncology, 2019, 28(7): 486-489.
[1]Dodd RL,Slevin NJ. Salivary gland adenoid cystic carcinoma:a review of chemotherapy and molecular therapies[J]. Oral Oncol,2006,42(8):759-769. DOI:10.1016/j.oraloncology.2006.01.001. [2]Bradley PJ. Adenoid cystic carcinoma of the head and neck:a review[J]. Curr Opin Otolaryngol Head Neck Surg,2004,12(1):127-132. DOI:10.1097/00020840-200404000-00013. [3]He SZ,Li PD,Zhong Q,et al. Clinicopathologic and prognostic factors in adenoid cystic carcinoma of head and neck minor salivary glands:a clinical analysis of 130 cases[J]. Am J Otolaryngol,2017,38(2):157-162. DOI:10.1016/j.amjoto.2016.11.014. [4]Amit M,Binenbaum Y,Sharma K,et al. Analysis of failure in patients with adenoid cystic carcinoma of the head and neck. An international collaborative study[J]. Head Neck,2014,36(7):998-1004. DOI:10.1002/hed.23405. [5]Lloyd S,Yu JB,Wilson LD,et alDeterminants and patterns of survival in adenoid cystic carcinoma of the head and neck,including an analysis of adjuvant radiation therapy[J]. Am J Clin Oncol,2011,34(1):76-81. DOI:10.1097/COC.0b013e3181 d26 d45. [6]Cao CN,Luo JW,Xu GZ,et al. Management of nasopharyngeal adenoid cystic carcinoma[J]. J Oral Maxillofac Surg,2013,71(4):e203-209. DOI:10.1016/j.joms.2012.12.024. [7]Gomez DR,Hoppe BS,Wolden SL,et al. Outcomes and prognostic variables in adenoid cystic carcinoma of the head and neck:a recent experience[J]. Int J Radiat Oncol Biol Phys,2008,70(5):1365-1372. DOI:10.1016/j.ijrobp.2007.08.008. [8]Shen CY,Xu TT,Huang CP,et al. Treatment outcomes and prognostic features in adenoid cystic carcinoma originated from the head and neck[J]. Oral Oncol,2012,48(5):445-449. DOI:10.1016/j.oraloncology.2011.12.002. [9]Liu XW,Xie CM,Li H,et al. Nasopharyngeal adenoid cystic carcinoma:magnetic resonance imaging features in ten cases[J]. Chin J Cancer,2012,31(1):19-28. DOI:10.5732/cjc.011.10242. [10]Subramaniam T,Lennon P,O Neill JP,et al. Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck[J]. Int J Med Sci,2015.184(3):583-90. DOI:10.1007/s11845-015-1298-1. [11]Al-Mamgani A,van Rooij P,Verduijn GM,et al. Long-term outcomes and quality of life of 186 patients with primary parotid carcinoma treated with surgery and radiotherapy at the Danielden Hoed Cancer Center[J]. Int J Radiat Oncol Biol Phys,2012,84(1):189-195. DOI:10.1016/j.ijrobp.2011.11.045. [12]Chen AM,Granchi PJ,Garcia J,et al. Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands:implications for adjuvant therapy[J]. Int J Radiat Oncol Biol Phys,2007,67(4):982-987. DOI:10.1016/j.ijrobp.2006.10.043. [13]温树新,唐平章,徐震纲,等. 鼻咽部腺样囊性癌的治疗体会[J]. 中华耳鼻咽喉头颈外科杂志,2006,41(2):359-361. Wen SX,Tang PZ,Xu ZG,et al. Experience in the treatment of adenoid cystic carcinoma of the nasopharyngeal gland[J]. Chine J Otolaryngol Head Neck Surg,2006,41(2):359-361. [14]Ryckman JM,Kusi-Appiah A,Simone CB,et al. Treatment approaches for nasopharyngeal adenoid cystic carcinoma[J]. Acta Oncol,2018,57(7):995-1001. DOI:10.1080/0284186X.2018.1426878. [15]Ko JJ,Siever JE,Hao D,et al. Adenoid cystic carcinoma of head and neck:clinical predictors of outcome from a canadiancentre[J]. Curr Oncol,2016,23(1):26-33. DOI:10.3747/co.23.2898. [16]Mendenhall WM,Morris CG,Amdur RJ,et al. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck[J]. Head Neck,2004,26(2):154-162. DOI:10.1002/hed.10380. [17]Bell RB,Dierks EJ,Homer L,et al. Management and outcome of patients with malignant salivary gland tumors[J]. J Oral Maxillofac Surg,2005,63(7):917-928. DOI:10.1016/j.joms.2005.03.006. [18]Lloyd S,Yu JB,Wilson LD,et al. Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck,including an analysis of adjuvant radiation therapy[J]. Am J Clin Oncol,2011,34(1):76-81. DOI:10.1097/COC.0b013e3181 d26 d45. [19]Liu TR,Yang AK,Guo X,et al. Adenoid cystic carcinoma of the nasopharynx:27-year experience[J]. Laryngoscope,2008,118(11):1981-1988. DOI:10.1097/MLG.0b013e3181801 d23. [20]Yin ZY,Wu XL,Hu YH,et alCylindroma of the nasopharynx:a chronic disease[J]. Int J Radiat Oneol Bioi Phys,1986,12(1):25-30. [21]Wang CC,See LC,Hang JH,et alNasopharyngeai adenoid cystic carcinoma:five new casefi and a literature review[J]. J Otolaryngol,1996,25(6):1399-1403. [22]Samant S,van den Brekel MW,Kies MS,et al. Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck[J]. Head Neck,2012,34(9):1263-1268. DOI:10.1002/hed.21905. [23]Bhattasali O,Holliday E,Kies MS,et al. Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma:a series of 9 cases and a critical review of the literature[J]. Head Neck,2016,38(Suppl 1):1472-1480. DOI:10.1002/hed.24262. [24]Pommier P,Liebsch NJ,Deschler DG,et al. Proton beam radiation therapy for skull base adenoid cystic carcinoma[J]. Arch Otolaryngol Head Neck Surg,2006,132(11):1242-1249. DOI:10.1001/archotol.132.11.1242. [25]Holliday E,Bhattasali O,Kies MS,et al. Postoperative intensity-modulated proton therapy for head and neck adenoid cystic carcinoma[J]. Int J Part Ther,2016,2(4):533-543. DOI:10.14338/IJPT-15-00032.1. [26]Takagi D,Fukuda S,Furuta Y,et al. Clinical study of adenoid cystic carcinoma of the head and neck[J]. Auris Nasus Larynx,2001,28 Suppl:S99-S102. DOI:10.1016/s0385-8146(01)00073-6. [27]Pfeffer MR,Talmi Y,Catane R,et al. A phase Ⅱ study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands[J]. Oral Oncol,2007,43(1):33-36. DOI:10.1016/j.oraloncology.2005.12.026.
2019, Vol. 28 
